Coexistence of essential thrombocythemia, iron-refractory iron deficiency anemia and renal cell carcinoma

Sinem Namdaroglu,1,2 Emre Tektunguz,2 Fevzi Altuntaş2
1Department of Hematology, 2Department of Hematology, Istanbul Bozyaka Education and Research Hospital; 2Department of Hematology, Ankara Oncology Research Hospital, Ankara, Turkey

Abstract

Essential thrombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm. It is characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow with JAK2V617F mutation. Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder, which is mainly characterized by iron deficiency anemia not responding to oral iron intake, but partially responding to parenteral iron therapy. Recently, it is shown that IRIDA has stemmed from mutations in the gene TMPRSS6, which encodes a transmembrane serine protease (matrilm-2) expressed by the liver. IRIDA patients indicate inappropriately increased levels of hepcidin which is a hormone delivered by the liver inhibiting iron absorption from the intestine and iron release from macrophage stores. According to recent studies, TMPRSS6 down-regulates hepcidin expression by cleaving hemojuvelin, a membrane-bound protein which triggers hepcidin signaling in hepatocytes.1

Renal cell carcinoma (RCC) accounts for 2-3% of all cancers.2 RCC, as the most common solid lesion in the kidneys, represents approximately 90% of all kidney malignancies.3 Many renal masses are asymptomatic and non-palpable till the late phases of the disease.4 Currently, more than half of the RCCs are identified incidentally through imaging while investigating some non-specific symptom complexes.5-7 The classic triad of flank pain, gross hematuria and palpable abdominal mass is uncommon (6-10%).8,9

Paraneoplastic syndromes are found in approximately 30% of patients with symptomatic RCCs. A few asymptomatic patients present with symptoms due to metastatic disease, such as bone pain or persistent cough.4,10 Ten to forty percent of patients with RCC experience paraneoplastic phenomena over the span of the disease. The symptom that may result in erythrophagocytosis is the most well-known paraneoplastic hematological event. Erythrophagocytosis is reported in 1 to 8% of the patients.11 Moderate granulocytosis and thrombocytosis appears in approximately 20% of the patients and is seen as part of a systemic inflammatory reaction as it is typically interrelated with anemia, fever, weight loss, and increased serum levels of CRP and interleukin-6.6,12 Here, we report a patient who presents with coexistence of RCC and thrombocytosis, which hasn’t been caused by hormonal factors that are produced in tumor cells. This patient has been therefore diagnosed with ET. The patient who was expected to display RCC with polycythemia, conversely present with IRIDA.

Introduction

Essential thrombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm (MPN). It is characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow with JAK2V617F mutation in 50-60% of patients. ET transforms into myelofibrosis in a minority of cases, while evolution to acute leukemia is uncommon and increases with the use of certain therapies. Survival of ET patients does not substantially differ from that of the general population. Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder. It is mainly characterized by iron deficiency anemia that is not responding to oral iron intake, but partially responding to parenteral iron therapy. Recently, it is shown that IRIDA has stemmed from mutations in the gene TMPRSS6, which encodes a transmembrane serine protease (matrilm-2) expressed by the liver. IRIDA patients indicate inappropriately increased levels of hepcidin which is a hormone delivered by the liver inhibiting iron absorption from the intestine and iron release from macrophage stores. According to recent studies, TMPRSS6 down-regulates hepcidin expression by cleaving hemojuvelin, a membrane-bound protein which triggers hepcidin signaling in hepatocytes.1

Case Report

A 56-years-old male presented with weakness and weight loss. Physical examination was unremarkable. His blood counts were: white blood cells: 9500×109/L; hemoglobin: 6.9 g/dL; mean corpuscular volume 58 fl.; platelets count: 1,423,000/mm3; C-reactive protein: 0.9 mg/L; serum iron: 5 μmol/L (normal range: 15-30 μmol/L); total iron-binding capacity: 505 μg/dL (normal range: 110-350 μg/dL); transferrin saturation: 1% (normal range: 20-45%); ferritin: 3.1 ng/mL (normal range: 20-330 ng/mL); sedimentation rate 23 (normal range: 0-20). The peripheral blood smear showed hypochromic and microcytic cells, anisopoikilocytosis and thrombocytosis while his liver and kidney tests were normal.

Endoscopy and colonoscopy was applied to the patient in order to determine the etiology of iron deficiency anemia and no pathological signs were found.

According to the etiology of thrombocytosis, JAK2V617F mutation was found as positive and Ph chromosome was negative in our patient. Serum erythropoietin level was 11.9 (normal range:3.5-17.6). Bone marrow biopsy showed megakaryocytic hyperproliferation, in which megakaryocytes are increased in size with mature hyperlobulated with abundant cytoplasm and grouped. Standard cytogenetic studies showed a normal male karyotype (46 XY) and FISH (fluorescence in situ hybridization) analysis for deletion 5q (del (5q)) was negative.

Abdominal computed tomography was applied to the patient to investigate the presence of other malignancies and a 35×32 mm solid renal mass was diagnosed. The biopsy of...
this mass showed clear cell RCC (cRCC).

During the examination of patient, oral iron treatment was used both to correct anemia. The hemoglobin concentration, serum iron level and ferritin level didn’t increase enough after four weeks. This failure is usually due to poor compliance, misdiagnosis, continued blood loss, or malabsorption but none of these reasons were present in our patient. Starch block electrophoresis of the hemoglobin was applied to him to investigate the underlying thalassemia, and the hemoglobin electrophoretic pattern was found normal. We suspected that the patient may have IRIDA, because all of its typical features as microcytic anemia with low serum iron, no response to oral iron, and only a partial response to intravenous iron therapy were present in our patient; however, we couldn’t identify mutations of the TMPRSS6 gene and high plasma levels of hepcidin due to technical difficulties.

As a result of all these investigations, the patient was found to have coexistence of RCC, ET and IRIDA.

Radical nephrectomy operation was planned for the patient by urologists. Before the operation cytoreductive therapy with hydroxyurea was administered to the patient until his platelet count is reduced below 400 000/mm³ and parenteral (intravenously) iron treatment was applied to the patient until the hemoglobin level increased at least above 10 g/dL.

**Discussion and Conclusions**

Platelet count can increase in a variety of conditions, such as anemia, reduced iron stores, inflammation, the absence of a spleen, and primary proliferative disorders. Of all these conditions, malignant neoplasms are one of the most frequent causes of thrombocytosis. Here we report a patient who presented with coexistence of RCC and thrombocytosis, but it hasn’t been caused by hormonal factors that are produced in tumor cells. He has been diagnosed with ET. This patient, who was suspected to have RCC polycythemia, conversely had IRIDA.

We aimed to show that coexistence of malignant neoplasms and thrombocytosis may not only arise from the production of humoral factors produced by the tumor, but concomitant MPN must be also considered.

**References**

1. Finberg KE. Iron-refractory iron deficiency anemia. Semin Hematol 2009;46:378-86.
2. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary. Lyon, 2001.
3. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
4. Novick AC, Bukowski RM, Campbell SC. Renal tumours. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh urology. Philadelphia: WB Saunders; 2007. pp. 1565-1638.
5. Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 2006;68:737-40.
6. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol 2006;176:896-9.
7. Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008;113:78-83.
8. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 2002;7:135-40.
9. Patard JJ, Leray E, Rodriguez A, et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 2003;44:226-32.
10. Kim HL, Beldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170:1742-6.
11. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol 2002;4:163-70.
12. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in theparaneoplastic inflammatory syndrome associated with renal cell carcinoma. Int J Cancer 1997;72:424-30.